View the Ethical Guidelines for Ketamine Clinicians
KRIYA Institute is devoted to understanding the therapeutic properties of ketamine (and related medicines). We provide clinical services directly to patients; we give presentations about therapeutic ketamine in a variety of settings; we offer consultation services to physicians and therapists; and we run KRIYA Conference, which was the first conference in the world devoted to the use of ketamine. Our mission is to bring together the most rigorous Science and an appreciation of Spirit in the study of psychospiritual medicines such as ketamine.
We have experience in using ketamine to help patients with severe unipolar depression (major depression), bipolar depression, suicidal ideation, OCD, pain with depression, and a number of other difficulties. We also have an interest in the use of ketamine as an adjunct to psychotherapy for personal exploration.*
We have worked with low dose ketamine following the research protocol; we have worked with moderate dose ketamine to provide ketamine-faciliated psychotherapy; and we have worked with high dose ketamine to induce dissociative and mystical experiences. We have experience with most of the routes of ketamine administration: IV (infusion), IM (injection), nasal, oral, transbuccal, sublingual, and transdermal. We believe that there is not one right way to use ketamine… we think that different patients are best served by different treatment strategies. We also have some experience with ketamine derivatives and other NMDA antagonists.
We would love to hear from you. You can email us at info@kriyainstitute.com or you can join our mailing list.
*The legal status of racemic (generic) ketamine is complex and involves multiple regulatory agencies. With respect to the DEA, ketamine is in Schedule III. With respect to the FDA, ketamine is FDA-approved for anesthesia, but it is not currently FDA-approved for any psychiatric or psychological indication; however, it can be used legally as an “off-label” treatment when certain criteria are met. To further complicate the picture, one enantiomer of ketamine (called “esketamine”) received FDA approval in 2019 for the treatment of refractory depression.